Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
370 participants
Study Classification
OBSERVATIONAL
Study Start Date
2018-07-01
Study Completion Date
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Rationale: Health related Quality of life (HRQoL) is impaired in patients with Turner and Klinefelter syndrome (TS and KS). It is unknown what the optimal endocrine treatment target values are that maximize HRQoL in patients with these syndromes. Therefore the relation between HRQoL and biochemical parameters will be studied in large cohorts of patients with TS and KS. This information will give essential insight that will help to improve endocrine treatment and HRQoL in these patients.
Research objectives: To explore the relationship between biochemical parameters and HRQoL in patients with TS and KS.
Hypothesis: Biochemical parameters are related to HRQoL in patients with TS and KS.
Study design: Cross-sectional, observational, multicentre study Study population: Patients with KS or TS, 18 years or older Methods and procedures: To measure fatigue the Checklist Individual Strength (CIS-20) will be used, for QoL the 5-level EQ-5D (EQ-5D-L5) will be used and for stress the Perceived Stress Scale (PSS) and hair cortisol levels. For patients with KS the anxiety scale from the Liebowitz social anxiety scale (LSAS) will be used to measure social anxiety. To measure the long-term exposure to testosterone in KS patients, testosterone concentrations in hair will be measured. For patients with KS, all questions from the questionnaires will be discussed orally during a visit to the outpatients clinic. One extra tube of blood and a strand of hair will be collected during routine blood withdrawal. All other variables are already part of the standard patient care and are available in patient records. For patients with TS all information including the questionnaires and laboratory values is already available and will be collected from clinical records.
Main study parameters/endpoints: The relationship between different hormonal parameters and HRQoL as measured by questionnaires. The main hormonal parameter that will be investigated in KS is testosterone in hair. For patients with Turner syndrome, free thyroxine (FT4), thyroid stimulating hormone (TSH) and liver enzymes, which have already been collected, will be investigated. The relationships between the EQ-5D-L5 score and testosterone in hair (in patients with KS) and thyroid hormone status (in patients with TS) are the primary outcomes.
Research objectives: To explore the relationship between biochemical parameters and HRQoL in patients with TS and KS.
Hypothesis: Biochemical parameters are related to HRQoL in patients with TS and KS.
Study design: Cross-sectional, observational, multicentre study Study population: Patients with KS or TS, 18 years or older Methods and procedures: To measure fatigue the Checklist Individual Strength (CIS-20) will be used, for QoL the 5-level EQ-5D (EQ-5D-L5) will be used and for stress the Perceived Stress Scale (PSS) and hair cortisol levels. For patients with KS the anxiety scale from the Liebowitz social anxiety scale (LSAS) will be used to measure social anxiety. To measure the long-term exposure to testosterone in KS patients, testosterone concentrations in hair will be measured. For patients with KS, all questions from the questionnaires will be discussed orally during a visit to the outpatients clinic. One extra tube of blood and a strand of hair will be collected during routine blood withdrawal. All other variables are already part of the standard patient care and are available in patient records. For patients with TS all information including the questionnaires and laboratory values is already available and will be collected from clinical records.
Main study parameters/endpoints: The relationship between different hormonal parameters and HRQoL as measured by questionnaires. The main hormonal parameter that will be investigated in KS is testosterone in hair. For patients with Turner syndrome, free thyroxine (FT4), thyroid stimulating hormone (TSH) and liver enzymes, which have already been collected, will be investigated. The relationships between the EQ-5D-L5 score and testosterone in hair (in patients with KS) and thyroid hormone status (in patients with TS) are the primary outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome
NCT00134745
Turner Syndrome
COMPLETED
PHASE4
Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome
NCT01585831
Klinefelter Syndrome
XXY Syndrome
COMPLETED
NA
Hormone Replacement Therapy to Treat Turner Syndrome
NCT00013546
Osteoporosis
Turner's Syndrome
COMPLETED
PHASE2
Klinefelter Syndrome and Testosterone Treatment in Puberty
NCT06294990
Klinefelter Syndrome
RECRUITING
PHASE4
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
NCT05586802
Klinefelter Syndrome
RECRUITING
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rationale: Health related Quality of life (HRQoL) is impaired in patients with Turner and Klinefelter syndrome (TS and KS). It is unknown what the optimal endocrine treatment target values are that maximize HRQoL in patients with these syndromes. Therefore the relation between HRQoL and biochemical parameters will be studied in large cohorts of patients with TS and KS. This information will give essential insight that will help to improve endocrine treatment and HRQoL in these patients.
Research objectives: To explore the relationship between biochemical parameters and HRQoL in patients with TS and KS.
Hypothesis: Biochemical parameters are related to HRQoL in patients with TS and KS.
Study design: Cross-sectional, observational, multicentre study
Study population: Patients with KS or TS, 18 years or older Methods and procedures: To measure fatigue the Checklist Individual Strength (CIS-20) will be used, for QoL the 5-level EQ-5D (EQ-5D-L5) will be used and for stress the Perceived Stress Scale (PSS) and hair cortisol levels. For patients with KS the anxiety scale from the Liebowitz social anxiety scale (LSAS) will be used to measure social anxiety. To measure the long-term exposure to testosterone in KS patients, testosterone concentrations in hair will be measured. For patients with KS, all questions from the questionnaires will be discussed orally during a visit to the outpatients clinic. One extra tube of blood and a strand of hair will be collected during routine blood withdrawal. All other variables are already part of the standard patient care and are available in patient records. For patients with TS all information including the questionnaires and laboratory values is already available and will be collected from clinical records.
Main study parameters/endpoints: The relationship between different hormonal parameters and HRQoL as measured by questionnaires. The main hormonal parameter that will be investigated in KS is testosterone in hair. For patients with Turner syndrome, free thyroxine (FT4), thyroid stimulating hormone (TSH) and liver enzymes, which have already been collected, will be investigated. The relationships between the EQ-5D-L5 score and testosterone in hair (in patients with KS) and thyroid hormone status (in patients with TS) are the primary outcomes.
Objectives:
Primary Objective:
To explore the relationship between thyroid hormone status\* and QoL as measured by the EQ-5D-5L in patients with TS.
To explore the relationship between testosterone concentrations in hair and QoL as measured by the EQ-5D-5L in patients with KS.
Secondary Objective(s):
For TS:
The relationship between thyroid hormone status\* and the CIS-20 and PSS scores. The relationship between liver enzymes\*\* and the EQ-5D-5L, CIS-20 and PSS scores.
The relationship between hair cortisol levels and the EQ-5D-5L, CIS-20 and PSS scores.
For KS:
The relationship between testosterone concentrations in hair and the CIS-20, LSAS and PSS scores.
The relationship between hair cortisol levels and the EQ-5D-5L, CIS-20, LSAS and PSS scores.
\*Variable that consists of the following 6 categories:
* Overt hyperthyroidism (FT4\>25pmol/L and TSH\<0,4mU/L)
* Overt hypothyroidism (FT4 \<11 pmol/L and TSH \>4,3 mU/L)
* Subclinical hypothyroidism with TSH \<10mU/L (FT4 11-25 pmol/L and TSH 4,3-10mU/L)
* Subclinical hypothyroidism with TSH \>10mU/L (FT4 11-25 pmol/L and TSH \> 10mU/L)
* Subclinical hyperthyroidism (FT4 11-25 pmol/L and TSH \<0,4 mU/L)
* Euthyroidism (FT4 11-25 pmol/L and TSH 0,4- 4,3 mU/L)
* aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, lactate dehydrogenase (LDH)
Study design:
2\. STUDY DESIGN This is study is a multicentre cross-sectional cohort study with the Erasmus Medical Centre (EMC), the VU University Medical Centre (VUmc) and the Amsterdam Medical Centre (AMC) as contributing centres. The duration of the study is 26 months.
The following data will be collected: laboratory values, fatigue scores, HRQoL scores, stress-scores, date of birth, age at diagnosis, height, weight, use of medication, genetic background, comorbidities. All information is already available in clinical records for patients with TS. For patients with KS information on HRQoL, fatigue and stress scores needs to be collected. A strand of hair to measure long-term testosterone and cortisol levels in hair and an extra tube of blood for storage will also be collected. This tube of blood could later be used to determine CAGn polymorphism in the androgen receptor, see paragraph below. Patients with KS visit an endocrinologist at the outpatients clinic of the AMC, VUmc or the EMC every one or two years and will be asked all questions of the questionnaires right after their appointment with the endocrinologist. The executive researcher will be present at the outpatients clinic to obtain informed consent and ask all questions. All laboratory values needed are routinely assessed at every visit for standard patient care and will be collected from clinical records afterwards.
2.1 Laboratory values
Laboratory outcomes:
For KS: luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone in blood and testosterone and cortisol levels in hair.
For TS: thyroid stimulating hormone (TSH), free T4 (fT4) and liver enzymes: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, lactate dehydrogenase (LDH) and cortisol levels in hair.
2.2 Genotype The classic form of KS, which is present in the 80-90 % of the cases, is defined by a 47,XXY karyotype. Higher-grade aneuploidies (e.g. 48,XXXY or 48,XXYY), structurally abnormal X chromosome (e.g. 47,iXq,Y) or mosaicisms (e.g. 47,XXY/46,XY) make up the remaining 10-20 % of cases.
The most common genetic background in TS patients is a 45,X karyotype, which is present in approximately 60% of TS patients. Around 20% of cases of TS are caused by a mosaicism 45X/46,XX and structural abnormalities chromosome X explain the last 20%. (26) As genetic background influences phenotype, information on karyotype from clinical records will be collected.
2.3 Questionnaires Checklist Individual Strength (CIS-20) To measure fatigue the Checklist Individual Strength (CIS-20) will be used. The CIS-20 consists of 20 questions that measure the amount of fatigue experienced by the subject during the last two weeks. The subject has to indicate on a 7 point Likertscale to what extent each statement applies to him or her. The CIS-20 consists of 4 subscales: subjective fatigue (8 questions), concentration (5 questions), motivation (4 questions) and activity (3 questions). The CIS-20 questionnaire has been validated in several populations and has proven to be a valid and reliable questionnaire for the assessment of fatigue. Utilization of the CIS-20 questionnaire is free, as long a reference to two articles is included in the publication.
5-level EQ-5D (EQ-5D-L5) To assess HRQoL the EQ-5D-L5 questionnaire will be used. This questionnaire consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). In the descriptive system the patient is asked to rate how many problems he or she experiences in the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The scores for these five dimensions can be combined to get a number that describes the health state of the respondent. The EQ VAS is also a measure of health outcome. The patient is asked to indicate on a visual analogue scale how good he or she thinks his or her health is. References values for the Dutch general population are available.
Perceived Stress Scale (PSS) To measure stress the PSS questionnaire will be used. The PSS consists of 10 questions that measure the degree of stress experienced by a subject after or during certain events during the preceding month. The PSS has proven to be a valid measure for perceived stress with good psychometric properties.
Liebowitz social anxiety scale (LSAS) To measure social anxiety in patients with Klinefelter syndrome, the LSAS will be used. The LSAS is widely used to measure social anxiety. It consists of two subscales: the scale for anxiety and for avoidance. Respondents are asked to rate their level of fear and avoidance in 24 social situations. Research shows good psychometric properties. Only the scale for anxiety will be used to minimize the burden for the patient.
2.4 Androgen receptor CAGn polymorphism A study by Zitzmann et al. showed an association between androgen receptor CAG repeats and androgen action. KS men with a shorter CAGn length seem to have less gynecomastia, bigger testis and higher bone density. When KS men with a shorter CAGn length receive testosterone replacement therapy, they show a better suppression of LH levels, prostate growth and higher haemoglobin concentrations. However, a more recent study by Valente et al. showed no relevant clinical differences in KS patients due to CAGn length variation on the androgen receptor. Therefore it is currently unclear whether CAG repeats are of clinical importance. Blood samples (buffy coat) will be collected and stored to be able to measure androgen receptor CAG repeats when the role of these CAGn polymorphisms has been clarified.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
For patients with KS: There are no risks associated with participation. All measurements will take place right after a planned visit at the outpatients clinic. All subjects with KS need to answer questions from four questionnaires, which will take about 30 minutes (including collection of informed consent). The biochemical parameters measured are already routinely assessed during the visits to the outpatients clinic. Only one extra tube of blood will be collected and stored. Blood will be collected during blood withdrawal for the assessment of laboratory values needed for standard care. One strand of hair will also be collected.The burden is therefore minimal.
For patients with TS: For patients with TS all information is already available. Therefore there will not be any burden or risk.
There is no direct benefit for the participants, but all patients with KS and TS could benefit from better hormonal treatment in the future due to the results of this study. When the questionnaires indicate severe psychological problems, psychological care will be offered.
Research objectives: To explore the relationship between biochemical parameters and HRQoL in patients with TS and KS.
Hypothesis: Biochemical parameters are related to HRQoL in patients with TS and KS.
Study design: Cross-sectional, observational, multicentre study
Study population: Patients with KS or TS, 18 years or older Methods and procedures: To measure fatigue the Checklist Individual Strength (CIS-20) will be used, for QoL the 5-level EQ-5D (EQ-5D-L5) will be used and for stress the Perceived Stress Scale (PSS) and hair cortisol levels. For patients with KS the anxiety scale from the Liebowitz social anxiety scale (LSAS) will be used to measure social anxiety. To measure the long-term exposure to testosterone in KS patients, testosterone concentrations in hair will be measured. For patients with KS, all questions from the questionnaires will be discussed orally during a visit to the outpatients clinic. One extra tube of blood and a strand of hair will be collected during routine blood withdrawal. All other variables are already part of the standard patient care and are available in patient records. For patients with TS all information including the questionnaires and laboratory values is already available and will be collected from clinical records.
Main study parameters/endpoints: The relationship between different hormonal parameters and HRQoL as measured by questionnaires. The main hormonal parameter that will be investigated in KS is testosterone in hair. For patients with Turner syndrome, free thyroxine (FT4), thyroid stimulating hormone (TSH) and liver enzymes, which have already been collected, will be investigated. The relationships between the EQ-5D-L5 score and testosterone in hair (in patients with KS) and thyroid hormone status (in patients with TS) are the primary outcomes.
Objectives:
Primary Objective:
To explore the relationship between thyroid hormone status\* and QoL as measured by the EQ-5D-5L in patients with TS.
To explore the relationship between testosterone concentrations in hair and QoL as measured by the EQ-5D-5L in patients with KS.
Secondary Objective(s):
For TS:
The relationship between thyroid hormone status\* and the CIS-20 and PSS scores. The relationship between liver enzymes\*\* and the EQ-5D-5L, CIS-20 and PSS scores.
The relationship between hair cortisol levels and the EQ-5D-5L, CIS-20 and PSS scores.
For KS:
The relationship between testosterone concentrations in hair and the CIS-20, LSAS and PSS scores.
The relationship between hair cortisol levels and the EQ-5D-5L, CIS-20, LSAS and PSS scores.
\*Variable that consists of the following 6 categories:
* Overt hyperthyroidism (FT4\>25pmol/L and TSH\<0,4mU/L)
* Overt hypothyroidism (FT4 \<11 pmol/L and TSH \>4,3 mU/L)
* Subclinical hypothyroidism with TSH \<10mU/L (FT4 11-25 pmol/L and TSH 4,3-10mU/L)
* Subclinical hypothyroidism with TSH \>10mU/L (FT4 11-25 pmol/L and TSH \> 10mU/L)
* Subclinical hyperthyroidism (FT4 11-25 pmol/L and TSH \<0,4 mU/L)
* Euthyroidism (FT4 11-25 pmol/L and TSH 0,4- 4,3 mU/L)
* aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, lactate dehydrogenase (LDH)
Study design:
2\. STUDY DESIGN This is study is a multicentre cross-sectional cohort study with the Erasmus Medical Centre (EMC), the VU University Medical Centre (VUmc) and the Amsterdam Medical Centre (AMC) as contributing centres. The duration of the study is 26 months.
The following data will be collected: laboratory values, fatigue scores, HRQoL scores, stress-scores, date of birth, age at diagnosis, height, weight, use of medication, genetic background, comorbidities. All information is already available in clinical records for patients with TS. For patients with KS information on HRQoL, fatigue and stress scores needs to be collected. A strand of hair to measure long-term testosterone and cortisol levels in hair and an extra tube of blood for storage will also be collected. This tube of blood could later be used to determine CAGn polymorphism in the androgen receptor, see paragraph below. Patients with KS visit an endocrinologist at the outpatients clinic of the AMC, VUmc or the EMC every one or two years and will be asked all questions of the questionnaires right after their appointment with the endocrinologist. The executive researcher will be present at the outpatients clinic to obtain informed consent and ask all questions. All laboratory values needed are routinely assessed at every visit for standard patient care and will be collected from clinical records afterwards.
2.1 Laboratory values
Laboratory outcomes:
For KS: luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone in blood and testosterone and cortisol levels in hair.
For TS: thyroid stimulating hormone (TSH), free T4 (fT4) and liver enzymes: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin, lactate dehydrogenase (LDH) and cortisol levels in hair.
2.2 Genotype The classic form of KS, which is present in the 80-90 % of the cases, is defined by a 47,XXY karyotype. Higher-grade aneuploidies (e.g. 48,XXXY or 48,XXYY), structurally abnormal X chromosome (e.g. 47,iXq,Y) or mosaicisms (e.g. 47,XXY/46,XY) make up the remaining 10-20 % of cases.
The most common genetic background in TS patients is a 45,X karyotype, which is present in approximately 60% of TS patients. Around 20% of cases of TS are caused by a mosaicism 45X/46,XX and structural abnormalities chromosome X explain the last 20%. (26) As genetic background influences phenotype, information on karyotype from clinical records will be collected.
2.3 Questionnaires Checklist Individual Strength (CIS-20) To measure fatigue the Checklist Individual Strength (CIS-20) will be used. The CIS-20 consists of 20 questions that measure the amount of fatigue experienced by the subject during the last two weeks. The subject has to indicate on a 7 point Likertscale to what extent each statement applies to him or her. The CIS-20 consists of 4 subscales: subjective fatigue (8 questions), concentration (5 questions), motivation (4 questions) and activity (3 questions). The CIS-20 questionnaire has been validated in several populations and has proven to be a valid and reliable questionnaire for the assessment of fatigue. Utilization of the CIS-20 questionnaire is free, as long a reference to two articles is included in the publication.
5-level EQ-5D (EQ-5D-L5) To assess HRQoL the EQ-5D-L5 questionnaire will be used. This questionnaire consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). In the descriptive system the patient is asked to rate how many problems he or she experiences in the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The scores for these five dimensions can be combined to get a number that describes the health state of the respondent. The EQ VAS is also a measure of health outcome. The patient is asked to indicate on a visual analogue scale how good he or she thinks his or her health is. References values for the Dutch general population are available.
Perceived Stress Scale (PSS) To measure stress the PSS questionnaire will be used. The PSS consists of 10 questions that measure the degree of stress experienced by a subject after or during certain events during the preceding month. The PSS has proven to be a valid measure for perceived stress with good psychometric properties.
Liebowitz social anxiety scale (LSAS) To measure social anxiety in patients with Klinefelter syndrome, the LSAS will be used. The LSAS is widely used to measure social anxiety. It consists of two subscales: the scale for anxiety and for avoidance. Respondents are asked to rate their level of fear and avoidance in 24 social situations. Research shows good psychometric properties. Only the scale for anxiety will be used to minimize the burden for the patient.
2.4 Androgen receptor CAGn polymorphism A study by Zitzmann et al. showed an association between androgen receptor CAG repeats and androgen action. KS men with a shorter CAGn length seem to have less gynecomastia, bigger testis and higher bone density. When KS men with a shorter CAGn length receive testosterone replacement therapy, they show a better suppression of LH levels, prostate growth and higher haemoglobin concentrations. However, a more recent study by Valente et al. showed no relevant clinical differences in KS patients due to CAGn length variation on the androgen receptor. Therefore it is currently unclear whether CAG repeats are of clinical importance. Blood samples (buffy coat) will be collected and stored to be able to measure androgen receptor CAG repeats when the role of these CAGn polymorphisms has been clarified.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
For patients with KS: There are no risks associated with participation. All measurements will take place right after a planned visit at the outpatients clinic. All subjects with KS need to answer questions from four questionnaires, which will take about 30 minutes (including collection of informed consent). The biochemical parameters measured are already routinely assessed during the visits to the outpatients clinic. Only one extra tube of blood will be collected and stored. Blood will be collected during blood withdrawal for the assessment of laboratory values needed for standard care. One strand of hair will also be collected.The burden is therefore minimal.
For patients with TS: For patients with TS all information is already available. Therefore there will not be any burden or risk.
There is no direct benefit for the participants, but all patients with KS and TS could benefit from better hormonal treatment in the future due to the results of this study. When the questionnaires indicate severe psychological problems, psychological care will be offered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Klinefelter Syndrome
Turner Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Klinefelter
Patients with Klinefelter syndrome
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Intervention Type
DIAGNOSTIC_TEST
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Turner
Patient with Turner syndrome
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Intervention Type
DIAGNOSTIC_TEST
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Klinefelter or Turner syndrome as confirmed by genetic testing
* Sufficient knowledge of the Dutch language to complete the questionnaires
* At least 18 years old
* Sufficient knowledge of the Dutch language to complete the questionnaires
* At least 18 years old
Exclusion Criteria
* KS: Patients not under treatment in the EMC, AMC or VUmc or no planned visits during the study period
* TS: No laboratory values or no questionnaires available in patient records
* Severe psychiatric or neurologic disorders or other reasons for inability to complete the questionnaires as assessed by the treating physician.
* Failure to obtain informed consent
* TS: No laboratory values or no questionnaires available in patient records
* Severe psychiatric or neurologic disorders or other reasons for inability to complete the questionnaires as assessed by the treating physician.
* Failure to obtain informed consent
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
dr. Laura C. G. de Graaff-Herder
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
dr. Laura C. G. de Graaff-Herder
Principal investigator
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura de Graaff, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Internal Medicine - Endocrinology, Erasmus MC, Rotterdam, the Netherlands
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Netherlands
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL65814.078.18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cardiometabolic Profiles of Boys With Klinefelter Syndrome
NCT02723305
COMPLETED
Effects of Adrenal Androgens on Gender-typed Behavior in Girls With Turner Syndrome
NCT05346159
COMPLETED
Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment
NCT02408445
COMPLETED
PHASE4
Androgen Effect on Klinefelter Syndrome Motor Outcome
NCT00348946
COMPLETED
PHASE2
Life Quality and Health in Patients With Klinefelter Syndrome
NCT01690013
COMPLETED
Thrombosis and Neurocognition in Klinefelter Syndrome
NCT02526628
COMPLETED
Human Chorionic Gonadotropin Stimulation Effects on Steroidogenesis in Men With Klinefelter Syndrome
NCT02788136
COMPLETED
NA
TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY
NCT03325647
COMPLETED
PHASE4
Pubertal Blockade and Hormone Therapy in Transgender Youth
NCT03557268
COMPLETED
Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth
NCT02550431
COMPLETED
Pharmacokinetic Study of Testosterone Enanthate
NCT01887418
COMPLETED
PHASE1/PHASE2
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
NCT00400335
COMPLETED
PHASE1
CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men
NCT00729859
COMPLETED
PHASE2
Hormone Secretion in Transgender Males
NCT04321551
WITHDRAWN
PHASE4
Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure
NCT00957034
TERMINATED
PHASE2
Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment
NCT02034487
COMPLETED
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
NCT00161421
COMPLETED
PHASE2
PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue
NCT00490555
COMPLETED
PHASE2/PHASE3
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
NCT00635817
COMPLETED
PHASE3
ORAL T-6: Oral Androgens in Man-6
NCT00663793
COMPLETED
PHASE1
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
NCT04831099
UNKNOWN
PHASE3
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
NCT01686828
COMPLETED
PHASE1/PHASE2
Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men
NCT04237467
COMPLETED